Geron Corporation Advances Blood Cancer Treatment with RYTELO™ and Upcoming Conference Discussion

Geron Corporation's Commitment to Advancing Blood Cancer Treatment

Geron Corporation, a biopharmaceutical company based in Foster City, California, is dedicated to revolutionizing the treatment landscape for blood cancers, particularly through its pioneering telomerase inhibitor, RYTELO™ (imetelstat). The company recently announces that its management team will engage in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024. This event highlights Geron's ongoing commitment to sharing insights about its innovative therapies and engaging with stakeholders in the healthcare community. The discussion will be accessible via a webcast on Geron's website, demonstrating the company's transparency and dedication to keeping the public informed.

RYTELO™ has already made a significant impact by receiving approval in the United States for the treatment of certain adult patients suffering from lower-risk myelodysplastic syndromes (LR-MDS) accompanied by transfusion-dependent anemia. This milestone underscores Geron's focus on addressing unmet medical needs within the hematologic cancer space. The company is not resting on its laurels; it is also advancing a pivotal Phase 3 clinical trial of imetelstat for patients with JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). This trial is critical as it seeks to evaluate the efficacy and safety of imetelstat in a patient population that has limited treatment options, further solidifying Geron’s role as a leader in the field.

Geron’s innovative approach centers around the inhibition of telomerase activity, a mechanism that is often elevated in malignant stem and progenitor cells within the bone marrow. By targeting telomerase, Geron aims to reduce cell proliferation and promote the death of malignant cells, thus improving treatment outcomes for patients facing these challenging conditions. The company is also exploring additional applications of imetelstat in other hematologic malignancies, showcasing its commitment to expanding the potential of this first-in-class therapy. Through these efforts, Geron Corporation is not only advancing its pipeline but also striving to make a meaningful difference in the lives of patients battling blood cancers.

In addition to its clinical advancements, Geron encourages interested parties to learn more about its mission and innovations by visiting its website or connecting on LinkedIn. The upcoming fireside chat at the Evercore ISI HealthCONx Conference serves as an important platform for the company to discuss its strategic vision and the transformative impact of its therapies on patients' lives. As Geron continues to push the boundaries of cancer treatment, its dedication to patient care remains at the forefront of its operations.